Metelimumab

美替木单抗

Report date: 2023/04/25 13:51:18

Base Information

Drug NameMetelimumab
Drug Alias NameAnti-transforming-growth-factor-beta-1 monoclonal antibody - Cambridge Antibody TechnologyTGF-β-1 monoclonal antibody - Cambridge Antibody TechnologyAnti-TGF-β-1 monoclonal antibody - Cambridge Antibody TechnologyHuman anti-TGF-β-1 monoclonal antibody - Cambridge Antibody TechnologyAnti-TGF-β - Genzyme +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTransforming growth factor beta 1 inhibitorsImmunomodulators
TargetsTransforming growth factor beta 1
Therapy Area/IndicationsFibrosisScleroderma, Systemic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCambridge Antibody TechnologyGenzyme Corp
Active IndicationsN/A
Inactive IndicationsFibrosisScleroderma, Systemic

Other Information

ATC CodeN/A
Related LinksWikipedia